Medindia

X

Antibodies Market expected to witness a robust CAGR of 12.5%

Tuesday, November 22, 2016 Drug News J E 4
Advertisement

NEW YORK, Nov. 21, 2016 /PRNewswire/ -- This report offers a 10-year forecast on the global market for antibodies between 2016 and 2026. The global antibodies market is expected to witness a robust CAGR of 12.5% over the forecast period. The study demonstrates market dynamics that are expected to influence the current environment and future status of the global antibodies market over the forecast period. The primary objective of this report is to offer updates on trends, drivers, restraints, value forecasts, and opportunities for manufacturers operating in the global antibodies market.

Global demand for antibodies is increasing with growing burden of chronic illnesses such as cancer, autoimmune disorders and others. Developed markets such as the U.S. and Europe are witnessing increasing demand for antibody-based drugs due to rising demand for better treatment options. To understand and analyse the market, the report is categorically split into four sections, viz. market analysis by drug type, end user, indication, and regions. The report analyses the global antibodies market in terms of value (US$ Mn).

The global antibodies market is segmented on the basis ofDrug typeEnd UserDisease IndicationRegionThe report begins with the market definition and defining different product types. This is followed by the overview on evolution of antibody based drugs. The market dynamics section includes FMI's analysis on key trends, drivers, restraints, opportunities and macro factors influencing global antibodies market. Impact analysis of key growth drivers and restraints based on weighted average model has also been included in the report to better equip clients with crystal clear decision making insights.

The next section of the report analyses the market based on drug type and presents the forecast in terms of value for the next 10 years. Drug types covered in the report include:Monoclonal antibodiesPolyclonal antibodiesAntibody drug conjugatesMonoclonal antibodies drug type segment holds highest market share in global antibodies market owing to high potential of these drugs for use in targeted therapies. Antibody-drug conjugates drug-type segment is expected to grow at significant CAGR over the forecast period due to unique property of exerting combined therapeutic effect of antibody and conjugated drug.The next section of the report analyses market based on end user and presents the forecast in terms of value for the next ten years. The end users covered in this report are:HospitalsLong-term care facilitiesResearch institutesThe next section of the report analyses the market based on indications and presents the forecast in terms of value for the next ten years. The indications covered in the report include:CNS DisordersCardiovascular DiseasesCancerAutoimmune disordersFurthermore, the report analyses the market based on regions and presents the forecast in terms of value for the next ten years. Regions covered in the report include:North AmericaU.S.CanadaLatin AmericaArgentinaBrazilMexicoRest of Latin AmericaWestern EuropeUKGermanyFranceSpainItalyNordicBeneluxRest of Western EuropeEastern EuropeRussiaPolandRest of Eastern EuropeAsia Pacific Excluding JapanChinaIndiaASEANAustralia & New ZealandRest of APEJMiddle East & Africa (MEAGCC CountriesSouth AfricaNorth AfricaRest of MEAJapanIn addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global antibodies market.Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the antibodies market. To understand key growth segments, the report provides the 'Attractiveness Index' analysis. The resulting index helps providers to identify real market opportunities.In the final section of the report on antibodies market, the 'Competitive Landscape' is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Key categories of providers covered in the report are drug types. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. However, this section also includes market strategies and SWOT analysis of the main players in the market.Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co.Read the full report: http://www.reportlinker.com/p04070841-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/antibodies-market-expected-to-witness-a-robust-cagr-of-125-300367003.html

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Retinoid x receptors Beta (RXRs) Agonists -Pipelin...
S
The National at 125 S Clark Selects LifeStart to M...